New Parkinson's drug aims to smooth out 'Off' episodes

NCT ID NCT06596876

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested a new drug called HRG2010 in 165 people with Parkinson's disease who experience motor fluctuations—times when their symptoms return before the next dose. The study compared HRG2010 to a standard sustained-release levodopa to see if it could reduce daily 'off' time (when movement is poor) and improve quality of life. Results will show whether this new formulation offers better symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HRG2010 (a new formulation of carbidopa/levodopa)
What this could lead to
If it works, this could offer a better way to manage motor fluctuations in Parkinson's disease, giving patients more stable symptom control throughout the day.
What could go wrong
This is a single phase 3 study with 165 participants, so results may not apply to all Parkinson's patients. The new drug may not prove significantly better than existing sustained-release levodopa, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Hospital

    Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.